View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 28, 2019updated 23 Nov 2021 8:16am

SpringWorks and GSK sign clinical trial collaboration agreement

SpringWorks Therapeutics has signed an agreement to assess its nirogacestat in combination with GlaxoSmithKline’s (GSK) belantamab mafodotin to treat patients with relapsed or refractory multiple myeloma.

SpringWorks Therapeutics has signed an agreement to assess its nirogacestat in combination with GlaxoSmithKline’s (GSK) belantamab mafodotin to treat patients with relapsed or refractory multiple myeloma.

Under the clinical trial collaboration agreement, GSK will sponsor and conduct an adaptive Phase Ib study to evaluate the safety, tolerability and preliminary efficacy of gamma-secretase inhibitor (GSI) nirogacestat in combination with anti-B-cell maturation antigen (BCMA) antibody-drug conjugate (ADC) belantamab mafodotin.

All development costs associated with the study will be assumed by GSK, which will also form a joint development committee along with SpringWorks Therapeutics to manage the clinical study.

SpringWorks Therapeutics CEO Saqib Islam said: “While significant advances have been made in treating multiple myeloma over the past decade, a significant unmet need remains for patients who have relapsed or are refractory to available treatments.

“We are delighted to enter into this agreement with GlaxoSmithKline, who also invested in our recent Series B financing, and we look forward to exploring the potential benefit of nirogacestat and belantamab mafodotin for multiple myeloma patients.”

Nirogacestat is an investigational, oral, selective, small molecule GSI that is currently in  Phase III clinical development for desmoid tumours. In June last year, the inhibitor received FDA Orphan Drug designation for the treatment of desmoid tumours. It also has fast-track designation.

Belantamab mafodotin is an investigational drug that is currently in Phase II clinical development for patients with relapsed/refractory multiple myeloma and other advanced hematologic malignancies expressing BCMA.

The drug secured Breakthrough Therapy designation in 2017 from the US FDA and PRIME designation from the European Medicines Agency.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology